Development and Assessment of a Multiplex Real-Time PCR Assay for Quantification of Human Immunodeficiency Virus Type 1 DNA

ABSTRACT Previous studies showed that high levels of human immunodeficiency virus type 1 (HIV-1) DNA are associated with a faster progression to AIDS, an increased risk of death, and a higher risk of HIV RNA rebound in patients on highly active antiretroviral therapy. Our objective was to develop and assess a highly sensitive real-time multiplex PCR assay for the quantification of HIV-1 DNA (RTMP-HIV) based on molecular beacons. HIV-1 DNA quantification was carried out by RTMP in a LightCycler 2.0 apparatus. HIV-1 DNA was quantified in parallel with CCR5 as a reference gene, and reported values are numbers of HIV-1 DNA copies/106 peripheral blood mononuclear cells (PBMCs). The clinical sensitivity of the assay was assessed for 115 newly diagnosed HIV-1-infected individuals. The analytical sensitivity was estimated to be 12.5 copies of HIV-1 DNA per 106 PBMCs, while the clinical sensitivity was 100%, with levels ranging from 1.23 to 4.25 log10 HIV-1 DNA copies/106 PBMCs. In conclusion, we developed and assessed a new RTMP-HIV assay based on molecular beacons, using a LightCycler 2.0 instrument. This multiplex assay has comparable sensitivity, reproducibility, and accuracy to single real-time PCR assays.

[1]  A. Hatzakis,et al.  The role of HIV-1 DNA as an additional marker of HIV-1 infection. , 2009, Current HIV research.

[2]  K. Bondeson,et al.  Simultaneous Detection of Chlamydophila pneumoniae and Mycoplasma pneumoniae by Use of Molecular Beacons in a Duplex Real-Time PCR , 2007, Journal of Clinical Microbiology.

[3]  M. Magnani,et al.  Fast and sensitive quantitative detection of HIV DNA in whole blood leucocytes by SYBR green I real-time PCR assay. , 2007, Molecular and cellular probes.

[4]  B. Gazzard,et al.  Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  G. d’Ettorre,et al.  Cellular HIV‐1 DNA quantitation in patients during simplification therapy with protease inhibitor‐sparing regimens , 2007, Journal of medical virology.

[6]  Michael S Saag,et al.  Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. , 2006, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[7]  Claus O. Wilke,et al.  Residual Human Immunodeficiency Virus Type 1 Viremia in Some Patients on Antiretroviral Therapy Is Dominated by a Small Number of Invariant Clones Rarely Found in Circulating CD4+ T Cells , 2006, Journal of Virology.

[8]  P. Morlat,et al.  CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  D. Nickle,et al.  HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. , 2005, The Journal of clinical investigation.

[10]  C. Rouzioux,et al.  Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4+ T cell counts. , 2005, The Journal of infectious diseases.

[11]  P. Henrivaux,et al.  Human immunodeficiency virus type 1 (HIV-1) proviral DNA load in purified CD4+ cells by LightCycler® Real-time PCR , 2005, BMC infectious diseases.

[12]  J. Goedert,et al.  Cellular HIV-1 DNA load predicts HIV-RNA rebound and the outcome of highly active antiretroviral therapy , 2004, AIDS.

[13]  Michael S Saag,et al.  Treatment for Adult HIV Infection 2006 Recommendations of the International AIDS Society–USA Panel , 2006 .

[14]  M. Re,et al.  Quantitative detection of human immunodeficiency virus type 1 (HIV-1) proviral DNA in peripheral blood mononuclear cells by SYBR green real-time PCR technique. , 2004, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[15]  M. Re,et al.  Quantitative detection of human immunodeficiency virus type 1 (HIV-1) viral load by SYBR green real-time RT-PCR technique in HIV-1 seropositive patients. , 2004, Journal of virological methods.

[16]  J. Lahuerta,et al.  The use of fluorescent molecular beacons in real time PCR of IgH gene rearrangements for quantitative evaluation of multiple myeloma. , 2004, Clinical and laboratory haematology.

[17]  T. Leitner,et al.  A multiplex real‐time PCR for quantification of HIV‐1 DNA and the human albumin gene in CD4+ cells , 2003, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[18]  J. Goedert,et al.  Quantitation of Human Immunodeficiency Virus Type 1 DNA Forms with the Second Template Switch in Peripheral Blood Cells Predicts Disease Progression Independently of Plasma RNA Load , 2002, Journal of Virology.

[19]  T. Benfield,et al.  Cell-associated HIV DNA Measured Early During Infection has Prognostic Value Independent of Serum HIV RNA Measured Concomitantly , 2002, Scandinavian journal of infectious diseases.

[20]  Thomas D. Schmittgen,et al.  Real-Time Quantitative PCR , 2002 .

[21]  J. Goedert,et al.  T cell receptor excision circles and HIV-1 2-LTR episomal DNA to predict AIDS in patients not receiving effective therapy , 2001, AIDS.

[22]  Giota Touloumi,et al.  Effect of recent thymic emigrants on progression of HIV-1 disease , 2000, The Lancet.

[23]  H. Sheppard,et al.  PCR-Based Assay To Quantify Human Immunodeficiency Virus Type 1 DNA in Peripheral Blood Mononuclear Cells , 2000, Journal of Clinical Microbiology.

[24]  M. Saag,et al.  Predictors of optimal virological response to potent antiretroviral therapy. , 1999, AIDS.

[25]  C. A. Macken,et al.  Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. , 1999, The New England journal of medicine.

[26]  M A Nowak,et al.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[27]  R. Siliciano,et al.  Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection , 1997, Nature.

[28]  K. Harada,et al.  Direct Observation of Vortex Dynamics in Superconducting Films with Regular Arrays of Defects , 1996, Science.

[29]  John W. Mellors,et al.  Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.

[30]  Sanjay Tyagi,et al.  Molecular Beacons: Probes that Fluoresce upon Hybridization , 1996, Nature Biotechnology.

[31]  J. Mellors,et al.  Quantitation of HIV-1 RNA in Plasma Predicts Outcome after Seroconversion , 1995, Annals of Internal Medicine.

[32]  A. Fauci,et al.  The immunopathogenesis of human immunodeficiency virus infection. , 1993, The New England journal of medicine.

[33]  J. Hartley,et al.  Use of uracil DNA glycosylase to control carry-over contamination in polymerase chain reactions. , 1990, Gene.

[34]  S. Kwok,et al.  Avoiding false positives with PCR , 1989, Nature.

[35]  N Gochman,et al.  Incorrect least-squares regression coefficients in method-comparison analysis. , 1979, Clinical chemistry.

[36]  Martin S. Hirsch,et al.  Treatment for adult HIV infection. , 2004 .

[37]  S. Hammer,et al.  Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy. , 2003, The Journal of infectious diseases.

[38]  Jo Vandesompele,et al.  RTPrimerDB: the Real-Time PCR primer and probe database , 2003, Nucleic Acids Res..

[39]  R. Siliciano,et al.  Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. , 2000, Annual review of immunology.

[40]  John L. Sullivan,et al.  Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy , 2000, Nature Medicine.